Global AAV Genome Sequencing Service Market Strategic Research Report

Scope of the Report

The global AAV Genome Sequencing Service market size is predicted to grow from US$ 221 million in 2025 to US$ 532 million in 2032; it is expected to grow at a CAGR of 13.2% from 2026 to 2032.

AAV Genome Sequencing Service refers to a specialized technical service that employs sequencing technologies (such as short-read NGS, PacBio SMRT, Oxford Nanopore) to comprehensively characterize the genome of Adeno-Associated Virus (AAV) vectors, covering aspects like the integrity of inverted terminal repeats (ITRs), transgene cassette accuracy, capsid gene variations, and the detection of truncated genomes or host integration events, which is essential for ensuring the safety, efficacy, and quality control of AAV vectors in gene therapy research, development, and manufacturing, while also supporting regulatory submissions and clinical translation.

The demand for AAV Genome Sequencing Service is surging driven by the rapid expansion of the global gene therapy market, where AAV vectors are the most widely used delivery tools; key drivers include the need for vector quality control in preclinical and clinical stages (such as verifying genome integrity, detecting contaminants, and assessing safety risks like host integration), the increasing regulatory requirements for comprehensive vector characterization, and the rising R&D investment in novel AAV serotypes and engineered capsids, creating substantial business opportunities for CROs, sequencing service providers, and biotech companies that offer high-throughput, long-read, and ITR-focused sequencing solutions, with additional potential in manufacturing QC, IND-enabling studies, and post-approval monitoring to reduce late-stage trial failures and accelerate time-to-market for gene therapies.

This report presents a comprehensive overview of the global AAV Genome Sequencing Service market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Sequencing Technology

• Short-Read NGS Sequencing
• Long-Read PacBio Sequencing
• Nanopore Sequencing

Segment by Target Region

• Full-Genome Sequencing
• TR-Region Sequencing
• Capsid Gene Sequencing

Segment by Application

• Wild-Type AAV
• Recombinant AAV (rAAV)

Segment by Application

• Preclinical R&D Sequencing
• Clinical Trial Sequencing
• Manufacturing QC Sequencing

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global AAV Genome Sequencing Service market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Preclinical R&D Sequencing, Clinical Trial Sequencing, Manufacturing QC Sequencing evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact